Alastair Mark Thompson

Alastair Mark Thompson's AcademicInfluence.com Rankings

Biology

#13190

World Rank

#16722

Historical Rank

Computational Biology

#304

World Rank

#305

Historical Rank

Genetics

#1465

World Rank

#1567

Historical Rank

biology Degrees

Download Badge

Biology

Alastair Mark Thompson's Degrees

Bachelors Biochemistry University of Oxford

Why Is Alastair Mark Thompson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alastair Mark Thompson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Landscape of somatic mutations in 560 breast cancer whole genome sequences (2016) (1574)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. (2016) (1176)
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019) (832)
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial (2014) (737)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures (2017) (644)
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator (2007) (497)
Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. (2017) (444)
Quantitative shear wave ultrasound elastography: initial experience in solid breast masses (2010) (421)
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer (2013) (377)
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. (2018) (375)
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial (2017) (359)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer (2008) (315)
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial (2011) (288)
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. (2018) (269)
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. (2011) (257)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study (2018) (256)
Invasive breast cancer: relationship between shear-wave elastographic findings and histologic prognostic factors. (2012) (245)
p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer (2013) (240)
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) (2010) (238)
Psychological, surgical, and sociodemographic predictors of pain outcomes after breast cancer surgery: A population-based cohort study (2014) (223)
Differentiating benign from malignant solid breast masses: value of shear wave elastography according to lesion stiffness combined with greyscale ultrasound according to BI-RADS classification (2012) (214)
Mathematical modelling of tumour invasion and metastasis (2000) (212)
Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. (2015) (206)
Cyclin D1 and breast cancer. (2006) (206)
Patient-calibrated agent-based modelling of ductal carcinoma in situ (DCIS): from microscopic measurements to macroscopic predictions of clinical progression. (2012) (204)
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo (2017) (204)
The topography of mutational processes in breast cancer genomes (2016) (198)
Neoadjuvant treatment of breast cancer. (2012) (195)
Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. (1990) (190)
CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations (2013) (176)
Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo (2004) (170)
DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability (2010) (167)
Histological evaluation of AMPK signalling in primary breast cancer (2009) (167)
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. (2012) (166)
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model (2009) (163)
Targeting AMPK: a new therapeutic opportunity in breast cancer. (2008) (161)
Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study (2013) (149)
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS) (2019) (146)
Ductal carcinoma in situ: to treat or not to treat, that is the question (2019) (131)
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis (2008) (124)
Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction (2016) (120)
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. (2011) (114)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. (2020) (110)
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study (2019) (110)
Therapeutic Targeting of Integrin αvβ6 in Breast Cancer (2014) (107)
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. (2015) (105)
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (2018) (105)
Usnic acid: a non-genotoxic compound with anti-cancer properties (2005) (103)
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy (2010) (101)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. (2021) (101)
Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle (2013) (99)
p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients (2011) (97)
Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome (2012) (95)
Lack of correlation of stem cell markers in breast cancer stem cells (2014) (94)
Phenformin as prophylaxis and therapy in breast cancer xenografts (2012) (94)
Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? (2013) (91)
Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer? (2013) (90)
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration (2016) (86)
Chronic preoperative pain and psychological robustness predict acute postoperative pain outcomes after surgery for breast cancer (2012) (85)
Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. (2006) (83)
Spatio-temporal modelling of the Hes1 and p53-Mdm2 intracellular signalling pathways. (2011) (81)
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer (2018) (80)
Chromosomal radiosensitivity in G2-phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics (2001) (79)
NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity (2012) (79)
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. (2018) (79)
Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast. (1993) (78)
Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials (2017) (77)
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. (2010) (75)
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells (2015) (75)
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer (2014) (75)
ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR (2012) (74)
Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial (2015) (72)
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy (2010) (71)
The circular RNome of primary breast cancer (2019) (70)
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. (2017) (67)
Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism (2012) (66)
The influence of field strength and different clinical breast MRI protocols on the outcome of texture analysis using foam phantoms. (2011) (66)
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer. (2016) (66)
Use of a Magnetic Tracer for Sentinel Lymph Node Detection in Early-Stage Breast Cancer Patients: A Meta-analysis (2016) (65)
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer (2014) (64)
A candidate molecular signature associated with tamoxifen failure in primary breast cancer (2008) (63)
Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome (2011) (61)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study (2012) (60)
Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. (2018) (60)
p53 mutation, deprivation and poor prognosis in primary breast cancer (2010) (59)
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial (2011) (59)
p53-Based cyclotherapy: exploiting the ‘guardian of the genome' to protect normal cells from cytotoxic therapy (2013) (58)
Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives (2014) (58)
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018) (56)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example (2012) (52)
Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer (2017) (52)
A Multiscale Mathematical Model of Tumour Invasive Growth (2016) (51)
Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. (2006) (50)
Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer (2012) (50)
Influence of the Nuclear Membrane, Active Transport, and Cell Shape on the Hes1 and p53–Mdm2 Pathways: Insights from Spatio-temporal Modelling (2012) (49)
Endoscopic palliative treatment for esophageal and gastric cancer: techniques, complications, and survival in a population-based cohort of 948 patients (2004) (47)
Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer (2001) (47)
New approaches for improving outcomes in breast cancer in Europe. (2015) (47)
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity (2017) (47)
MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism (2008) (46)
P53 and breast cancer. (1993) (44)
The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer (2009) (44)
Physical oncology: a bench-to-bedside quantitative and predictive approach. (2011) (44)
Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation (1999) (44)
Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. (2018) (44)
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. (2013) (44)
Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). (2016) (44)
Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer (2014) (43)
Spironolactone use and risk of incident cancers: a retrospective, matched cohort study (2016) (41)
Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (2016) (40)
MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. (2020) (40)
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study (2010) (38)
Prospective Study of Psychosocial Outcomes of Having Contralateral Prophylactic Mastectomy Among Women With Nonhereditary Breast Cancer. (2018) (37)
The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). (2019) (37)
Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. (2018) (37)
TP53 drives invasion through expression of its Δ133p53β variant (2016) (36)
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity (2017) (36)
MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4 (2015) (36)
Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. (2010) (36)
SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer (2019) (35)
NT5E CpG island methylation is a favourable breast cancer biomarker (2012) (34)
The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention (2018) (33)
High frequency of complex TP53 mutations in CNS metastases from breast cancer (2011) (33)
Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays (2015) (33)
The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer (2010) (32)
Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA (2018) (32)
HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma (2010) (32)
Mathematical Oncology: How Are the Mathematical and Physical Sciences Contributing to the War on Breast Cancer? (2010) (32)
Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis (2019) (31)
Does usnic acid affect microtubules in human cancer cells? (2010) (31)
Diabetes, metformin, and breast cancer: lilac time? (2012) (31)
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. (2012) (30)
Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. (2017) (28)
Collagen Prolyl Hydroxylases Are Bifunctional Growth Regulators in Melanoma. (2018) (28)
Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy for Primary Breast Cancer Comparing Interim Ultrasound, Shear Wave Elastography and MRI (2017) (27)
Longitudinal analysis of patient‐reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole‐breast irradiation (2016) (27)
Genetic aspects of breast cancer. (1991) (26)
Morbidity and mortality rates following gastric cancer surgery and contiguous organ removal, a population based study. (2005) (26)
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer (2020) (26)
The RNA helicase/transcriptional co-regulator, p68 (DDX5), stimulates expression of oncogenic protein kinase, Polo-like kinase-1 (PLK1), and is associated with elevated PLK1 levels in human breast cancers (2014) (25)
Macroscopic handling and reporting of breast cancer specimens pre‐ and post‐neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches (2015) (25)
Ribosomal RNA 2′O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer (2020) (25)
The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer (2016) (25)
Identifying suspected breast cancer: development and validation of a clinical prediction rule. (2011) (25)
FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype (2011) (25)
Differential contextual responses of normal human breast epithelium to ionizing radiation in a mouse xenograft model. (2010) (25)
Development of 18F-fluorinatable dendrons and their application to cancer cell targeting (2011) (24)
Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ (2019) (24)
CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer (2018) (24)
The radiological features, diagnosis and management of screen-detected lobular neoplasia of the breast: Findings from the Sloane Project. (2016) (24)
Stoichiometric Quantification of Akt Phosphorylation Using LC-MS/MS (2009) (23)
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy (2010) (23)
Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival (2018) (23)
Randomised controlled trial of exercise to prevent shoulder problems in women undergoing breast cancer treatment: study protocol for the prevention of shoulder problems trial (UK PROSPER) (2018) (23)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. (2019) (23)
Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast. (2014) (22)
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project (2020) (22)
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer (2015) (21)
The role of signal transduction in cancer treatment and drug resistance. (2002) (21)
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin (2019) (21)
Multiparameter DNA content analysis identifies distinct groups in primary breast cancer (2013) (20)
Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters (2013) (20)
Beyond the Margins—Economic Costs and Complications Associated With Repeated Breast-Conserving Surgeries (2017) (19)
Doxorubicin and vinorelbine act independently via p53 expression and p38 activation respectively in breast cancer cell lines (2003) (19)
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic (2021) (18)
Gene signature of metformin actions on primary breast cancer within a window of opportunity randomized clinical trial. (2010) (18)
Surgical oncology: Why biopsying metastatic breast cancer should be routine (2010) (17)
Surgeon perception versus reality: Opioid use after breast cancer surgery (2019) (17)
Characterization, chemical optimization and anti-tumor activity of a tubulin poison identified by a p53-based phenotypic screen (2008) (17)
Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. (2017) (17)
HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice (2013) (17)
Classification and Immunohistochemical Scoring of Breast Tissue Microarray Spots (2013) (17)
Immunohistochemical analysis of breast tissue microarray images using contextual classifiers (2013) (16)
Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy (2018) (16)
Classification of breast-tissue microarray spots using colour and local invariants (2008) (16)
Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients (2021) (16)
Tumor localization in tissue microarrays using rotation invariant superpixel pyramids (2015) (16)
Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients (2020) (16)
Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse (2012) (16)
Optimizing Radiotherapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. (2020) (16)
A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. (2012) (15)
An evolutionarily conserved, alternatively spliced, intron in the p68/DDX5 DEAD-box RNA helicase gene encodes a novel miRNA. (2011) (15)
Comparison of mammographic findings after intraoperative radiotherapy or external beam whole breast radiotherapy. (2014) (15)
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma (2012) (15)
Do participants in adjuvant breast cancer trials reflect the breast cancer patient population? (2015) (15)
Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes (2018) (14)
Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer? (2019) (14)
Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2008) (14)
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer (2016) (13)
Bridging the age gap in breast cancer: cluster randomized trial of the effects of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices. (2021) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
The Informatics Challenges Facing Biobanks: A Perspective from a United Kingdom Biobanking Network (2015) (13)
Prädiktion der pathologischen Komplettremission nach neoadjuvanter Chemotherapie bei primärem Mammakarzinom mittels Interim Ultraschall, Shearwave-Elastografie und MRT (2017) (12)
Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. (2010) (12)
Functional Tumor Volume by Fast Dynamic Contrast‐Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple‐Negative Breast Cancer (2021) (12)
A mathematical model for the effect of a false-negative sentinel node biopsy on breast cancer mortality: a tool for everyday use (2005) (12)
Bridging The Age Gap: observational cohort study of effects of chemotherapy and trastuzumab on recurrence, survival and quality of life in older women with early breast cancer (2021) (12)
Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins (2018) (11)
Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation (2020) (11)
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial (2021) (11)
Imaging features of triple-negative breast cancers according to androgen receptor status. (2019) (10)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
∆Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stem‐like cells in human ER+ and HER2+ breast cancers (2019) (10)
The importance of nonpharmacogenetic factors in endocrine therapy. (2012) (10)
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (2019) (10)
Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. (2020) (9)
Variability in grading of ductal carcinoma in situ among an international group of pathologists (2021) (9)
Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: Results of a phase 0 clinical trial (2016) (9)
Neoadjuvant Pertuzumab‐containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER‐2/neu‐positive Breast Cancer: A Retrospective, Single Institution Experience (2018) (9)
Tumour bed clip localisation for targeted breast radiotherapy: compliance is proportional to trial-related research activity: tumour bed clip localisation in breast radiotherapy. (2014) (9)
Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. (2020) (9)
Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study). (2018) (9)
Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32 (2017) (9)
At last, a predictive and prognostic marker for radiotherapy? (2010) (9)
Breast MRI in DCIS size estimation, breast-conserving surgery and oncoplastic breast surgery. (2021) (8)
A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345. (2017) (8)
Classification of breast tissue-microarray spots using texton histograms (2008) (8)
The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. (2021) (8)
Genetic risk factors in breast cancer (2006) (8)
The effect of metformin vs placebo on sex hormones in CCTG MA.32. (2020) (8)
The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model (2012) (8)
Molecular determinants of post-mastectomy breast cancer recurrence (2018) (8)
Activity of MDI-301, a novel synthetic retinoid, in xenografts (2004) (8)
Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring (2001) (8)
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036 (2021) (8)
New standards of care in the management of the axilla (2012) (7)
The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group (2017) (7)
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC) (2020) (7)
Therapeutic Discovery Trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism (2012) (7)
A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy. (2012) (7)
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple‐negative breast cancer (2021) (7)
INSPIRE: An Integrated Agent Based System for Hypothesis Generation within Cancer Datasets (2008) (7)
Evidence for the multistep theory of carcinogenesis in human breast cancer (1992) (7)
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. (2020) (7)
SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC). (2017) (7)
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. (2020) (7)
Guidelines for regional genetic centres on the implementation of genetic services for the breast, ovarian and colorectal cancer families in Scotland (2000) (7)
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (2009) (6)
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. (2016) (6)
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer (2020) (6)
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). (2013) (6)
Analysis of stereotactic biopsies performed on suspicious calcifications identified within 24 months after completion of breast conserving surgery and radiation therapy for early breast cancer: Can biopsy be obviated? (2017) (6)
Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome (2020) (6)
Breast cancer (non-metastatic). (2007) (6)
Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ (2021) (6)
Scoring of Breast Tissue Microarray Spots through Ordinal Regression (2009) (6)
Biomarker discordance: prospective and retrospective evidence that biopsy of recurrent disease is of clinical utility. (2012) (6)
An analysis and hypothesis generation platform for heterogeneous cancer databases (2012) (6)
Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). (2018) (5)
Observational cohort study in older women with early breast cancer: use of radiation therapy and impact on health-related quality of life and mortality. (2021) (5)
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial (2020) (5)
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018) (5)
Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study) (2015) (5)
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. (2019) (5)
A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). (2017) (5)
Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers (2019) (5)
Molecular lesions in breast cancer. (1990) (5)
Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. (2015) (5)
A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. (2022) (5)
The automated detection of clusters of microcalcifications (1992) (5)
Effects of Standard Treatments for Ductal Carcinoma In Situ-Making Informed Choices. (2016) (4)
CA15-3/MUC1 in CCTG MA-32 (NCT01101438): A phase III RCT of the effect of metformin vs. placebo on invasive disease free and overall survival in early stage breast cancer (BC). (2018) (4)
Tumour segmentation in breast tissue microarray images using spin-context (2012) (4)
The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review (2020) (4)
Dissecting the molecular mechanisms of human cancer: translating laboratory advances into clinical practice. (2004) (4)
Prognostic and predictive factors in breast cancer: An overview (2008) (4)
The EORTC 10041/BIG 03–04 MINDACT (Microarray in Node Negative and 1 to 3 Positive Lymph Node Disease May Avoid ChemoTherapy) Trial: Patients' Baseline Characteristics and Logistics Aspects After a Successful Accrual (2011) (4)
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer (2022) (4)
Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. (2019) (4)
DCIS genomic signatures define biology and clinical outcome: Human Tumor Atlas Network (HTAN) analysis of TBCRC 038 and RAHBT cohorts (2021) (4)
Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial (2020) (4)
Are There Alternative Strategies for the Local Management of Ductal Carcinoma in Situ? (2018) (4)
Accelerated Partial Breast Irradiation and Intraoperative Partial Breast Irradiation: Reducing the Burden of Effective Breast Conservation. (2020) (3)
De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. (2020) (3)
1213 POSTER Tamoxifen adherence and its relationship to mortality in women with breast cancer (2007) (3)
p 53 mutant breast cancer patients expressing p 53 γ have as good a prognosis as wild-type p 53 breast cancer patients (2017) (3)
Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). (2021) (3)
Reply to R.F. Sweis et al. (2017) (3)
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients (2019) (3)
BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. (2021) (3)
Very low risk of locoregional breast cancer recurrence in the EORTC 10041/BIG 03-04 MINDACT trial: Analysis of risk factors including the 70-gene signature (2018) (3)
The time-varying effect of radiotherapy after breast-conserving surgery for DCIS (2019) (3)
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer (2013) (3)
Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443). (2019) (3)
p53 and γ radiation in the normal breast (2009) (3)
Breast conservation therapy versus mastectomy for breast cancer. (2020) (3)
Reply to “Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project” (2021) (3)
Abstract OT2-01-14: Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489) (2017) (3)
Abstract P5-05-05: Computational modeling of breast cancer growth and spread: the role of matrix degrading enzymes (2012) (2)
Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. (2020) (2)
Spin-context Segmentation of Breast Tissue Microarray Images (2013) (2)
Importance of long-term follow-up of women receiving adjuvant therapy for breast cancer in the community. (2011) (2)
What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS? (2017) (2)
Milking the stroma in triple-negative breast cancer (2012) (2)
WP 1 : Cell Biology , Autopoiesis and Biological Design Patterns D 1 . 4 : Mathematical Models of Gene Expression Computing (2)
Beyond the margins: Economic costs and complication rates associated with repeated breast-conserving surgeries. (2016) (2)
Structural chromosome analysis in peripheral blood lymphocytes of individuals belonging to breast cancer pedigrees suggest an association of genetic instability with a proportion of breast cancer in families not linked to the BRCA-1 gene (1994) (2)
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial (2021) (2)
Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices (2021) (2)
Abstract P4-07-04: Genomic analysis of paired DCIS and subsequent recurrence to assess clonal relatedness in screen detected DCIS (2020) (2)
Abstract B046: Therapeutic targeting of integrin αvβ6 in high-risk breast cancer (2013) (2)
Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study) (2022) (2)
Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. (2011) (2)
The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy. (2019) (2)
Undissected Axilla and Axillary Radiotherapy. (2019) (1)
Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers (2017) (1)
Medicine & surgery : an integrated textbook (2007) (1)
100. Changes in TGFB mRNA expression in breast cancer patients treated with tamoxifen (1995) (1)
Correction: Physical Oncology: A Bench-to-Bedside Quantitative and Predictive Approach (2011) (1)
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer (2015) (1)
Abstract P2-16-09: Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS) (2020) (1)
Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ (DCIS): Comparison of patients with and without index surgery. (2020) (1)
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). (2014) (1)
Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stage triple negative breast cancer (TNBC). (2020) (1)
What is the future for surgical oncology? (2011) (1)
Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease (2016) (1)
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC). (2021) (1)
Abstract P1-21-07: The Patient-reported Outcomes after Routine Treatment of Atypical Lesions (PORTAL) study: Pain, psychosocial wellbeing, and quality of life among women undergoing guideline concordant care for DCIS vs. active surveillance for in situ and atypical lesions (2020) (1)
Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer (2018) (1)
Prospective assessment of psychosocial outcomes of contralateral prophylactic mastectomy. (2017) (1)
Abstract P4-06-05: Heterogeneity of DCIS does not appear to be a biomarker for development of subsequent invasive cancer (2020) (1)
Abstract P4-15-13: When is cancer not really cancer? The PREvent ductal carcinoma in situ invasive overtreatment now (PRECISION)* initiative (2018) (1)
The frequency of methylation of the NT5E gene in metastatic breast cancer. (2011) (1)
Are baseline mammographic and ultrasound features associated with metastasis free survival in women receiving neoadjuvant chemotherapy for invasive breast cancer? (2021) (1)
Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial (2021) (1)
The clinical relevance of p53 isoforms modifying the effects of p53 mutation on survival from breast cancer (2007) (1)
Cluster analyses of the TCGA and a TMA dataset using the coexpression of HSP27 and CRYAB improves alignment with clinical-pathological parameters of breast cancer and suggests different epichaperome influences for each sHSP (2022) (1)
Scoring of breast tissue microarrays using ordinal regression: local patches vs. nuclei segmentation (2009) (1)
Women’s triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer (TNBC) using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (NACT). (2015) (1)
Abstract PD5-06: Impact of an online ductal carcinomain situ(DCIS) decision support tool on awareness of treatment options and knowledge of breast cancer risks (2021) (1)
Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS). (2016) (1)
Less Remains Better: Morbidity After Axillary Surgery (2015) (1)
Do participants in major, practice-changing breast cancer trials reflect the breast cancer patient population? (2013) (1)
Abstract PS4-05: Prospective evaluation of the gut microbiome and response to neoadjuvant therapy (NAT) in early-stage triple negative breast cancer (TNBC) (2021) (1)
Abstract P3-07-23: CYP2D6 genotype and breast cancer recurrence in tamoxifen treated patients: An evaluation of the importance of loss-of-heterozygosity (2016) (1)
Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer (2022) (1)
Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer (2021) (1)
Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer (2012) (1)
Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo (2021) (1)
Abstract PD6-06: Radiomic phenotypes from dynamic contrast-enhanced MRI (DCE-MRI) parametric maps for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients (2021) (1)
Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer (2021) (1)
Expression of TGFβ isoforms in breast cancer (1994) (1)
Analysis of breast tissue microarrays using latent Dirichlet allocation (2009) (1)
Changes in cognitive function in postmenopausal women 1 year after completing adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. (2010) (1)
Abstract CT076: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (1)
Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer (2018) (1)
Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) (2017) (0)
Abstract P6-02-10: Early ultrasound evaluation for prediction of treatment response to neoadjuvant chemotherapy in triple negative breast cancer patients (2019) (0)
The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease (2021) (0)
Abstract 1497: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized trial (ARTEMIS; NCT02276443) (2020) (0)
Abstract P2-10-05: The impact ofTP53mutation and pathological response to neoadjuvant chemotherapy on triple negative breast cancer outcomes (2018) (0)
A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) (2019) (0)
Computational identification of tumour suppressor protein p53 target genes (2007) (0)
TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). (2017) (0)
Abstract PD8-05: POSNOC - Positive sentinel node: Adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy (2019) (0)
Abstract P4-18-01: Do participants in adjuvant breast cancer trials reflect the breast cancer patient population? (2015) (0)
0-65. Allelic imbalance at chromosome 17p13.3(YNZ22) and poor prognosis in breast cancer (1997) (0)
Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients. (2019) (0)
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial (2021) (0)
Abstract P3-14-07: Intra-cellular dsRNA receptor RIG-I: A ubiquitous novel target for treatment of chemotherapy drug resistant breast cancer (2016) (0)
Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. (2019) (0)
Abstract PS3-08: Assessment of early response to neoadjuvant systemic therapy (NAST) of triple-negative breast cancer (TNBC) using chemical exchange saturation transfer (CEST) MRI: A pilot study (2021) (0)
Abstract P1-11-04: Looking beyond the margins: Economic costs and complications associated with repeated breast-conserving surgeries (2017) (0)
Effect of neoadjuvant chemotherapy regimen choice in patients with breast cancer with pathologic complete response. (2017) (0)
Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). (2018) (0)
0-64. pS2 expression provides additional useful prognostic information after 7 years follow-up (1997) (0)
Abstract PS16-03: Clonal relatedness of LCIS with synchronous and asynchronous invasive disease (2021) (0)
Abstract P3-08-09: Is it me or is it hot in here? Hot flushes (or flashes): An unmet need. UK NCRI breast clinical studies group working party on symptom management (vasomotor) (2013) (0)
Evaluation of a Breast Mass (2010) (0)
Abstract P4-02-04: Quantitative MRI features analysis for differentiation of triple negative and HER2 positive subtypes of breast cancer (2018) (0)
Intraoperative Radiotherapy: Is it Ready for Prime Time? (2015) (0)
Integration of Pathology, Radiology, and in vitro Data in Patient-Calibrated Cancer Simula- tions: Recent Advances and Future Outlook for Ductal Carcinoma In Situ (DCIS) (2012) (0)
103 P - Induction of expression of tumour TGFβ2 MRNA is associated with response to tamoxifen in breast cancer (1996) (0)
92OThe Breast International Group (BIG) AURORA pilot study for molecular screening in metastatic breast cancer (MBC) patients (2015) (0)
Abstract P3-08-08: SOX11 is a potential prognostic marker of high-risk breast ductal carcinomain situ (2019) (0)
Metformin effects on breast cancer cell proliferation, AMPK pathway and the cell cycle (2012) (0)
The Nonsurgical Management of Ductal Carcinoma In Situ (DCIS) (2018) (0)
Title : 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer (0)
Predictive Approach Physical Oncology : A Bench-to-Bedside Quantitative and Updated Version (2011) (0)
On the Practicalities of Translational Radiobiology: Lessons from IORT (Intra-operative Radiotherapy) (2007) (0)
Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. (2022) (0)
Abstract P1-02-01: HER2/neu antibody-fluorophore conjugate for intraoperative detection of HER2-positive breast cancer (2020) (0)
Abstract P1-07-02: Withdrawn (2018) (0)
Abstract P1-05-05: eEF1A2 facilitates PTEN-GSK3β mediated Aurora-A protein degradation during S-G2 phase inactivated in PTEN-deficient breast cancer (2019) (0)
Beyond detection: biological physics informing progression and treatment of cancer (2012) (0)
Sentinel node biopsy in ductal carcinoma in situ of breast - a meta-analysis (2007) (0)
Abstract P4-15-04: A longitudinal cohort study to identify risk factors for the development of invasive cancer in unresected DCIS (2018) (0)
Abstract PD2-03: Recurrent functionally diverse in-frameESR1gene fusions drive endocrine resistance in breast cancer (2017) (0)
Abstract OT-08-02: Comparing an operation to monitoring, with or without endocrine therapy (COMET): A prospective randomized trial for low-risk DCIS (AFT-25) (2021) (0)
Constitutional p53mutation inanon-Li-Fraumeni cancerfamily (1992) (0)
Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer. (2010) (0)
Abstract 787: Cytosolic TRIM24 characterizes an aggressive subset of ER- PR- and TP53 mutant breast cancer (2018) (0)
46 Adherence to adjuvant endocrine therapy for breast cancer: women's experiences of taking tamoxifen, letrozole and anastrozole (2014) (0)
Genetics and Molecular Biology of Breast Cancer, 2–6 September 1992. Cold Spring Harbor Laboratory, New York (1992) (0)
Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study) (2016) (0)
Comprar Medicine and Surgery | Alastair M. Thompson | 9780443072604 | Churchill Livingstone (2007) (0)
A gap analysis for breast cancer research: identifying translational priorities (2013) (0)
Diseases of the breast (2007) (0)
Abstracts from the 2015 Annual Scientific Meeting of the BHS (2015) (0)
Abstract 855: p53 isoform Ä133p53â triple negative breast cancer and increased relapse with neoadjuvant taxanes (2016) (0)
The Human Tumor Atlas Network (HTAN) Breast PreCancer Atlas: A multi-omic integrative analysis of ductal carcinoma in situ with clinical outcomes (2021) (0)
A pre-operative prognostic model predicting all cause and cause specific mortality for women presenting with invasive breast cancer. (2021) (0)
The effect of acquisition parameter changes on the outcome of texture analysis using a clinical breast MRI sequence on a foam phantom at 1 . 5 T (2011) (0)
Statistical modeling of a novel clinical trial design using neoadjuvant therapy (NAT) to personalize therapy in patients (pts) with triple-negative breast cancer (TNBC). (2020) (0)
Correction to: SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer (2020) (0)
Abstract LB-095: Aurora-A is elevated in cancer cells due to inactivation of EF1A2-PTEN-GSK3b regulated late S-G2 phase specific degradation pathway (2019) (0)
Evidence for involvement of the breast cancer 1 (BRCA1) gene in sporadic breast cancer (1993) (0)
Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial. (2020) (0)
Abstract A16: Metformin is a potential nontoxic adjuvant to enhance the efficacy of non-PDL1/PD-1 targeting immune therapies (2020) (0)
43. Evidence for co-expression of p53 and c-myc in breast cancer (1995) (0)
Abstract PD5-09: Mouse-intraductal (MIND): The first in vivo model to recapitulate the full spectrum of human DCIS pathology (2021) (0)
Identifying women at increased risk of breast cancer: Can we use genotyping at low penetrance loci? (2011) (0)
Abstract PD5-08: The human tumor atlas network (HTAN) breast pre cancer atlas: A multi-omic integrative analysis of ductal carcinoma in situ (DCIS) and correlation with clinical outcomes (2021) (0)
Abstract P5-05-06: Spatio-temporal computational modeling of the p53-Mdm2 pathway (2012) (0)
Abstract P5-05-02: The role of cellular heterogeneity on the therapeutic response of breast cancer: Clinical insights from a hybrid multiscale computational model (2012) (0)
Abstract PD12-06: Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) (0)
Percutaneous sentinel node removal using a vacuum-assisted needle biopsy in women with breast cancer: a feasibility and acceptability study. (2019) (0)
Abstract P1-05-14: Multiscale computational modeling of breast cancer invasion: Towards a predictive patient-based tool (2012) (0)
Abstract PD6-07: Volumetric changes on longitudinal dynamic contrast enhanced MR imaging (DCE-MRI) as an early treatment response predictor to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients (2021) (0)
A Comparison of Breast Cancer Radiotherapy Treatment Rates in British Columbia, Scotland, and Western Australia, and a Comparison with Models of “Optimal” Therapy (2010) (0)
Impact of TP53 mutations in Triple Negative Breast Cancer (2022) (0)
Abstract PS18-04: Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT) (2021) (0)
Abstract P1-07-22: Androgen receptor positivity is associated with nodal disease in triple negative breast cancer (2018) (0)
Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. (2017) (0)
Abstract P4-15-10: Second breast events after DCIS: Where, what and when? (2018) (0)
The evaluation of vacuum assisted breast biopsy for the diagnosis and treatment of non benign breast pathology, a retrospective cohort study (2013) (0)
Estrogen regulation of p53 isoforms in the human breast cancer cell line MCF7. (2009) (0)
Abstract OT2-01-20: Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC) (2017) (0)
CHAPTER III : II, MOLECULAR LESIONS IN BREAST CANCER (1990) (0)
Abstract P3-12-11: Combining Genotype at Low Penetrance Breast Cancer Loci with Family History Risk Leads to Significant Risk Reclassification (2010) (0)
2098 Initial Results of a Multi-center Trial Utilizing Xoft Axxent Electronic Brachytherapy to Deliver Intraoperative Radiation Therapy in the Treatment of Early-stage Breast Cancer (2010) (0)
Disparities in surveillance imaging after breast conserving surgery for primary DCIS. (2021) (0)
Abstract P5-05-01: A molecularly annotated collection of breast cancer patient-derived xenograft models aligned with ongoing clinical trials built from fine needle aspiration samples throughout neoadjuvant treatment (2018) (0)
Abstract P1-10-20: Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC) (2020) (0)
Deciding priorities in a clinical studies group (2010) (0)
Abstract P1-15-06: Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy (2019) (0)
Abstract 634: SOX11 is a potential clinical marker for hormone receptor negative ductal carcinoma in situ (2018) (0)
Title 2 Psychological , surgical and sociodemographic predictors of pain outcomes after breast 3 cancer surgery : a population-based cohort study 4 5 ( ii ) Full names of authors 6 (2013) (0)
Opioid prescriptions after breast cancer surgery: Perception and reality. (2018) (0)
Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial (2021) (0)
Abstract P4-14-02: CSF1/CSF1R axis reprograms epithelial-to-mesenchymal phenotypes in inflammatory breast cancer (2018) (0)
Abstract P3-01-01: Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC) (2019) (0)
Screen-detected lobular neoplasia of the breast: Findings from the Sloane Project (2016) (0)
Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial (2017) (0)
Abstract 4550: NT5E promoter methylation is a favorable breast cancer epigenetic biomarker (2012) (0)
DCIS and sentinel lymph node biopsy (2015) (0)
Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early-stage breast cancer: Findings from the Breast International Group (BIG) 1-98 trial. (2012) (0)
Abstract P2-11-02: Three-year outcomes with hypofractionated (HF) versus conventionally fractionated (CF) whole breast irradiation (WBI) (2018) (0)
Abstract PD6-7: Pathological features and lessons learned from screen detected ductal carcinoma in situ (DCIS) - Results from 11 337 cases in the UK Sloane project (2020) (0)
NIHMS662581-supplement-Supplementary data (2016) (0)
EUSOMA - Biology of breast cancer, 10–11 November 1994, London, UK (1995) (0)
Ductal Carcinoma in Situ (2018) (0)
53. Breast cancer survival at 5 years is defined by pS2 expression and node status (1995) (0)
11. Association of 17q with 11q allele loss and with 5-year survival in human breast cancer. (1995) (0)
Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. (2020) (0)
98O The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL) (2020) (0)
A prospective cohort study to analyse the effect of socioeconomic deprivation on breast cancer stage at diagnosis, treatment allocation and outcomes in older women in the United Kingdom. (2022) (0)
Abstract P6-17-04: 3-year relapse-free survival of stage II-III HER2-neu positive breast cancer treated with pertuzumab and trastuzumab-containing neoadjuvant therapy compared to trastuzumab-containing therapy (2019) (0)
Abstract P6-02-03: Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients (2020) (0)
Abstract 1994: Defining peritumoral and tumoral stromal gene signatures associated with response to neoadjuvant chemotherapy in breast cancer (2017) (0)
Preoperative estimation of the prognosis of invasive breast cancer, based on ultrasound size, core biopsy grade and percutaneous axillary lymph node biopsy (2011) (0)
70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer: Updated Results MINDACT (2020) (0)
Towards the automated prescreening of breast X-rays (1992) (0)
Abstract P4-15-02: Impact of radiotherapy and endocrine therapy on further events: Final multivariate analysis of a prospective, national cohort study of screen detected ductal carcinoma in situ (DCIS) of the breast (2018) (0)
British Society of Breast Radiology Annual Scientific Meeting 2017 (2017) (0)
Abstract P1-13-04: Prevention of shoulder problems trial (UK-PROSPER): Exercise to prevent shoulder problems in patients undergoing breast cancer treatment (2020) (0)
Abstract PD5-03: Ipsilateral invasive cancer risk after diagnosis with ductal carcinoma in situ in patients with and without index surgery: The effects of endocrine therapy and radiation treatment (2021) (0)
Abstract P3-11-11: A Comparison of Breast Cancer Treatment Rates in British Columbia, Scotland, and Western Australia, and a Comparison with Models of “Optimal” Therapy (2010) (0)
Abstract OT2-03-03: Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy (2016) (0)
Abstract P2-01-11: SentimagIC: A non-inferiority trial comparing super paramagnetic iron oxide vs. Tc99 and blue dye in the detection of axillary sentinel nodes in patients with early stage breast cancer (2017) (0)
Abstract P2-16-08: Longitudinal response and selection under neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443) (2020) (0)
Abstract PD5-02: Dcis as a risk lesion for invasive breast cancer and death from other cancers (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alastair Mark Thompson?

Alastair Mark Thompson is affiliated with the following schools:

Université libre de Bruxelles
MD Anderson Cancer Center
University of Dundee
Baylor College of Medicine
Okayama University
Baylor University
King's College London

Alastair Mark Thompson's Academic­Influence.com Rankings

Alastair Mark Thompson's Degrees

Why Is Alastair Mark Thompson Influential?

Alastair Mark Thompson's Published Works

Published Works

What Schools Are Affiliated With Alastair Mark Thompson?

Alastair Mark Thompson's AcademicInfluence.com Rankings